Cargando…
New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways
Schizophrenia is a disease affecting up to 1% of the population. Current therapies are based on the efficacy of chlorpromazine, discovered over 50 years ago. These drugs block dopamine D2-like receptors and are effective at primarily treating positive symptoms in a subset of patients. Unfortunately,...
Autores principales: | Perez, Stephanie M, Lodge, Daniel J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085299/ https://www.ncbi.nlm.nih.gov/pubmed/25061280 http://dx.doi.org/10.2147/DDDT.S42708 |
Ejemplares similares
-
Hippocampal interneuron transplants reverse aberrant dopamine system function and behavior in a rodent model of schizophrenia
por: Perez, Stephanie M., et al.
Publicado: (2013) -
O9.5. ABERRANT DOPAMINE SYSTEM FUNCTION REVERSED BY THE OREXIN RECEPTOR ANTAGONIST TCS1102 IN A RODENT MODEL OF SCHIZOPHRENIA
por: Perez, Stephanie, et al.
Publicado: (2018) -
Increased Presynaptic Dopamine Synthesis Capacity Is Associated With Aberrant Dopamine Neuron Activity in the Methylazoxymethanol Acetate Rodent Model Used to Study Schizophrenia-Related Pathologies
por: Perez, Stephanie M, et al.
Publicado: (2022) -
Orexin Modulation of VTA Dopamine Neuron Activity: Relevance to Schizophrenia
por: Perez, Stephanie M, et al.
Publicado: (2021) -
Increasing Endocannabinoid Levels in the Ventral Pallidum Restore Aberrant Dopamine Neuron Activity in the Subchronic PCP Rodent Model of Schizophrenia
por: Aguilar, David D, et al.
Publicado: (2014)